Summary
Global Markets Direct’s, ‘Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Pipeline Review, H2 2016’, provides in depth analysis on Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) targeted pipeline therapeutics.
The report provides comprehensive information on the Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.
Scope
- The report provides a snapshot of the global therapeutic landscape for Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL)
- The report reviews Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) targeted therapeutics and enlists all their major and minor projects
- The report assesses Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
3SBio Inc
AkaRx Inc
Amgen Inc
Intas Pharmaceuticals Ltd
Novartis AG
Shionogi & Co Ltd
STATegics Inc
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) Overview 7
Therapeutics Development 8
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Products under Development by Stage of Development 8
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Products under Development by Therapy Area 9
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Products under Development by Indication 10
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Products under Development by Companies 13
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Products under Development by Universities/Institutes 15
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Companies Involved in Therapeutics Development 23
3SBio Inc 23
AkaRx Inc 24
Amgen Inc 25
Intas Pharmaceuticals Ltd 26
Novartis AG 27
Shionogi & Co Ltd 28
STATegics Inc 29
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Drug Profiles 30
avatrombopag - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
eltrombopag olamine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
eltrombopag olamine - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
GSK-2285921 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
lusutrombopag - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Monoclonal Antibody to Agonize Thrombopoietin Receptor for Thrombocytopenia - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
romiplostim - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
romiplostim biosimilar - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
STST-4 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
thrombopoietin - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
thrombopoietin - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Dormant Projects 50
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Discontinued Products 51
Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Featured News & Press Releases 52
Aug 25, 2016: Health Canada issues advisory on REVOLADE citing risk of severe hepatotoxicity 52
Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder 53
May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association 54
Apr 19, 2016: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia 55
Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP 57
Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag 58
Dec 01, 2015: Shionogi Launches MULPLETA Tablets 3mg In Japan for Improvement of Thrombocytopenia 59
Sep 28, 2015: Shionogi Receives Marketing and Manufacturing Approval in Japan for MULPLETA Tablets 3mg for Improvement of Thrombocytopenia 59
Sep 02, 2015: Novartis receives EU approval for new Revolade use as first-in-class therapy for patients with severe aplastic anemia 60
Aug 24, 2015: FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia 61
Jul 24, 2015: Novartis drug Revolade recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder 62
Jun 12, 2015: FDA Approves Promacta for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication 63
Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder 64
May 27, 2015: Amgen To present data from Nplate study at the 20th Congress of the EHA 66
Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade) 66
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69
List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by 3SBio Inc, H2 2016 23
Pipeline by AkaRx Inc, H2 2016 24
Pipeline by Amgen Inc, H2 2016 25
Pipeline by Intas Pharmaceuticals Ltd, H2 2016 26
Pipeline by Novartis AG, H2 2016 27
Pipeline by Shionogi & Co Ltd, H2 2016 28
Pipeline by STATegics Inc, H2 2016 29
Dormant Projects, H2 2016 50
Discontinued Products, H2 2016 51
List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 21
